The importance of IL-6 blockade beyond the COVID-19 pandemic: consideration for cancer care

The novel human Coronavirus (SARS-CoV-2), which outbroke in Wuhan (China) in late 2019, is now responsible for the pandemic diffusion of COVID-19 [1 –3]. Researchers are working on the validation of effective protocols, including antiviral therapies and vaccines [4]. Case-fatality rate seems correlated with virally-driven hyperinflammation [4,5]. In this sense, recent data suggest a crucial role for cytokines release syndrome (CRS) and human i nterleukin-6 (IL-6) levels as fatality predictors [4,5].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: COVID-19 Rapid Letter Source Type: research